New pyrrolopyridine-based thiazolotriazoles as diabetics inhibitors: enzymatic kinetics and in silico study.
Muhammad TahaFazal RahimShawkat HayatSridevi ChigurupatiKhalid Mohammed KhandSyahrul Imran Abu BakarSyed Adnan Ali ShahNizam UddinShatha Ghazi FelembanVijayan VenugopalPublished in: Future medicinal chemistry (2023)
Aim: To synthesize pyrrolopyridine-based thiazolotriazoles as a novel class of α-amylase and α-glucosidase inhibitors and to determine their enzymatic kinetics. Methodology: Pyrrolopyridine-based thiazolotriazole analogs ( 1-24 ) were synthesized and characterized through proton nuclear magnetic resonance, carbon-13 nuclear magnetic resonance and high-resolution electron ionization mass spectrometry. Results: All synthesized analogs displayed good inhibitory potential of α-amylase and α-glucosidase ranging 17.65-70.7 μM and 18.15-71.97 μM, respectively, compared with the reference drug, acarbose (11.98 μM and 12.79 μM). Analog 3 was the most potent among the synthesized analogs, having α-amylase and α-glucosidase inhibitory activity at 17.65 and 18.15 μM, respectively. The structure-activity relationship and binding modes of interactions between selected analogs were confirmed via docking and enzymatic kinetics studies. The compounds ( 1-24 ) were tested for cytotoxicity against the 3T3 mouse fibroblast cell line and were observed to be nontoxic.
Keyphrases
- molecular docking
- magnetic resonance
- molecular dynamics simulations
- high resolution
- mass spectrometry
- hydrogen peroxide
- structure activity relationship
- liquid chromatography
- contrast enhanced
- gas chromatography
- type diabetes
- molecular dynamics
- oxide nanoparticles
- computed tomography
- small molecule
- magnetic resonance imaging
- human health
- aqueous solution
- climate change
- binding protein
- nitric oxide
- tandem mass spectrometry
- adverse drug
- anti inflammatory
- adipose tissue
- high performance liquid chromatography
- insulin resistance
- case control
- capillary electrophoresis
- dna binding